 glucose, urea, creatinine, total proteins, albumins, total bilirubin, triglycerides and cholesterol. 
INTRODUCTION
Epilepsy is the most common neurological disorder in dogs. Irrespective of the cause epilepsy is treated with antiepileptic drugs. Despite being often described as an "old fashioned" drug phenobarbitone is still the drug of first choice in the treatment of epilepsy in dogs (Lane and Bunch. 1990; McNamara, 1996; Rambeck, 2001; Berendt, 2002) . The anticonvulsive effect of this drug is achieved when its blood serum concentration reaches 15 µg/mL -45 µg/mL (65 mmol/L -193 mmol/L) (Farnbach, 1984; Lane and Bunch, 1990 ; Sisson, 1990; Boothe, 1996) . Some authors report the best therapeutic results when blood serum phenobarbitone concentration is 20 µg/mL -40 µg/mL (Frey, 1989; LeCouter, 1995; Podell, 1996) .
Despite the fact of being a safe drug the data published up to now report that therapy with phenobarbitone can cause a number of changes in the biochemical blood serum profile. A number of studies carried out on dogs Gaskill et al., 2005) report increased activities of alanine transaminase (ALT) and alkaline phosphatase (AP). Increased ALT and AP activities were mainly recorded in patients who did not display clinical signs of hepatopaties. Similar results were reported for humans, however this was not an indication for changing the drug or its dose (Lippi et al., 2008) . Contrary to these findings are those reported by Daryell and Hart (2008) who recorded increased AP and ALT activities accompanied by signs of hepatotoxicity as the result of phenobarbitone treatment. Dogs suffering from phenobarbitone iatrogenic hepatotoxicity displayed clinical signs such as disorientation, confusion, anorexy, icterus and ascites.
There are some controversies if phenobarbitone treatment can cause increased AST activity as a consequence of enzyme induction. AST can increase as a result of phenobarbitone treatment in humans (Verma and Haidukewych, 1994) and rats (Attia and Aref, 1991) . Despite the fact that increased AST activity caused by increased enzyme induction in dogs is possible (center, 1995) a study on Beagle dogs treated with high phenobarbitone doses for over 3 weeks (Tettenborn et al., 1973 ) and a study on 12 dogs of different breeds treated with 5 mg/kg/day for 27 weeks did not confirm this hypothesis (Müller et al., 2000) .
A transient statistically significant increase in albumin and total protein concentration during epilepsy treatment with phenobarbitone in a dose of 10 mg/kg/day for 27 weeks was reported by Müller et al. (2000) . Similar results were obtained in a study on 95 dogs treated with phenobarbitone doses in a range from less than 2 mg/kg/day up to over 10 mg/kg/day (Aitken et al., 2003) . However, in a trial carried out on 10 dogs receiving phenobarbitone 6 mg/kg/day during 12 weeks there was no statistically significant change in total protein and albumin blood concentrations compared to the untreated control (Foster et al., 2000) . Statistically significant differences in albumin and total protein concentrations were not recorded in a study on 10 dogs treated with phenobarbitone in doses from 3.9 mg/kg/day to 14.4 mg/kg/day (Foster et al., 2000) .
Literature data on the effects of phenobarbitone on serum bilirubin concentration indicate that the concentration of bilirubin does not change depending on phenobarbitone concentration (Foster et al., 2000) or duration of treatment (Chauvet, 1995) . However, an increased bilirubin concentration above referent values was recorded in dogs suffering from hepatotoxicity as a consequence of phenobarbitone treatment (Dayrell-Hart et al., 1991) .
The aim of this research was to study the effects of different per os therapeutic phenobarbitone doses on biochemical blood parameters in order to establish if the duration of the treatment affects enzyme activities in treated dogs.
MATERIAL AND METHODS

Animals:
The experiment was carried out on 30 dogs allotted into two experimental groups. The first group of 15 healthy dogs was treated with per os phenobarbitone at different therapeutic doses and the second group consisted of dogs suffering idiopathic epilepsy treated with phenobarbitone.
The first experimental group: The first group consisted of 15 male healthy experimental mongrels, 2-8 years of age and body weight 10.3 -25 kg. At the start of the experiment the dogs were clinically examined and treated twice with antihelmintic Cestal plus (CEVA / Phylaxia). The accomodation period was 21 days, during which the dogs were vaccinated against infective diseases with Duramune DA 2 LP + P i (Fort Dodge Laboratories, Iowa, USA) and Rabicel (Veterinarski zavod A. D., Zemun). The experiment was set in such a way that dogs received phenobarbitone at doses which were changed at three week intervals. Blood samples were taken each time the dose was changed and blood cell count, serum biochemistry and phenobarbitone concentration were determined. The experiment took place for 9 weeks and the pr os applied doses were 2 mg/kg/12h, 5 mg/kg/12h and 8 mg/kg/12h. Thereon, phenobarbitone was applied to the same dogs in an average dose of 8 mg/kg/12h for 11 weeks (a total of 14 weeks with this dose). During this period, starting from week four, blood samples were taken weekly and blood cell count, serum biochemistry and phenobarbitone concentration were determined.
The second experimental group: The second experimental group consisted of 15 mixed breed dogs of both sexes (4 females and 11 males), body mass 3.5 -49 kg and 2 to 4.5 years of age, all of which were diagnosed idiopathic epilepsy. The dogs were treated with phenobarbitone from one to five years. The females were ovariohysterectomized and the males were left intact. The starting phenobarbitone dose for this group was 2 mg/kg/12h per os. As long as phenobarbitone serum concentration was smaller than adviced the per os dose was not changed until sezures developed, and this was so three weeks after the start of the treatment. During the trial the dose of the drug was increased only if the frequency of the sezures was unacceptable. Prior to each dose change a thorough clinical and biochemical examination of the dog was carried out.
Blood samples. Blood samples were taken by sterile venepunction of the v. cephalicae antebrachi with a 0.9 gauge needle. The prepared plasma and serum blood samples were analyzed on the same day on which they were taken with the exeption of serum samples from the first group of dogs. These samples were frozen at -20 o C and phenobarbitone determination was done at monthly intervals. Serum samples taken from the second group of animals (dogs suffering from idiopathic epilepsy) phenobarbitone concentration was determined in fresh samples with no previous freezing. The tested biochemical parameters were: glucose, urea, creatinine, triglycerides, cholesterol, total proteins, albumin, total bilirubin concentrations, and AST, AP, ALT enzyme activities. The biochemical panel was determined on an automatic analyzer Basic -Sekomam (France) with J.T. Baker (Holland) reagents. The serum phenobarbitone concentration was measured at the Deparment of Toxicological Chemistry, Center for Poison Control at the Military Medical Academy (Belgrade) by HPLC at 254 nm.
Analysis. Statistical data analysis was completed with the Statistica 5.0 software. Results are given by descriptive statistical methods (mean value SV, standard deviation SD, and standard error SE). Comparison between groups was done with Student's t-test for a small sample and the multifactorial analysis by MANOVA (multifactorial variance analysis). Statistical significance was accepted at the level of p<0.05.
RESULTS AND DISCUSSION
On analyses of the results in the first group of healthy dogs three weeks after the start of phenobarbitone therapy in a dose of 4 mg/kg/day (2 mg/kg/12h) a statistically significant increase was measured only for AP. Within the same group of experimental dogs, after the first three weeks of treatment with 10 mg/kg/day (5 mg/kg/12h) phenobarbitone, a statistically significant increase was measured both for AP and ALT. Studies on the effect of a 14 weeks phenobarbitone treatment on blood biochemical parameters of healthy dogs at an average per os dose of 16 mg/kg/day (starting at 4 weeks, at weekly intervals) have shown a significant increase in AP (Figure 1 ) and ALT activities (Figure 2) . Results have shown ALT activities increased when the phenobarbitone dose reached 10 mg/kg/day and reached a high statistical significance (p<0.01) at 16 mg/kg/day. During the 14 weeks of phenobarbitone treatment ALT activity increased throughout the trial which resulted with a statistically significant increase by the end of the trial (Figure 2 ).
The group of dogs suffering from idiopathic epilepsy (second group) and receiving phenobarbitone at doses of 4 mg/kg/day and 6 mg/kg/day a statistically significant increase of AP was measured. Per os treatment with 8 mg/kg/day phenobarbitone resulted in an even more dramatic increase in AP activity ( Figure  3 ) accompanied with increased ALT activity (Figure 4) . When the unadequate response to 10 mg/kg/day phenobarbitone antiepileptic therapy was observed the measured ALT and AP activities were significantly higher. At the average dose of 13 mg/kg/day a significant (p<0.05) decrease in albumin and total protein concentrations was measured, as well as a significant (p<0.01) increase in ALT and AP activities. At a higher therapeutic dose of 16 mg/kg/day when an unadequate effect was recorded a significant decrease (p<0.05) of albumin and total proteins and increased values for total bilirubin (Figure 8) were measured. The same phenobarbitone dose induced a statistically significant increase in ALT and AP activities.
In the second group of dogs suffering from idiopathic epilepsy ALT activities increased depending on phenobarbitone dose. In this group significantly higher (p<0.05) ALT activities were measured at phenobarbitone doses of 8 and 10 mg/kg/day and recorded values were even higher (p<0.01) for second group had an increasing trend in AP activities with increasing phenobarbitone doses. Two of the dogs from the second group with high AP values were lethargic, weak, disoriented and with poor appetite. One of these two dogs had an obviously enlarged abdomen.
The AP activity in the blood serum of dogs treated with phenobarbitone is highly individual which is clearly shown by the large differences between the activity levels. The obtained variations are in accordance to the existing published data (Foster et al., 2000) .
A number of authors states that phenobarbitone application in dogs results in increased serum AP and ALT activities which are not accompanied by clinical signs of liver disease (Fanuel-Barret and Vivier, 1993; Chauvet et al., 1995; Center, 1995; Booth, 1996; Dowling, 1999; Müller et al., 2000; Foster et al., 2001; Aitken et al., 2003) . In support of this finding are the results of our study with the difference that in the group of dogs suffering from idiopathic epilepsy after treatment with 16 mg/kg/day phenobarbitone two dogs had clinical symptoms of hepatotoxicity. AP activity in the dog number 11 was 1112 U/L and ALT activity was 292 U/L. For the dog number 14 AP and ALT activities were 745 U/L and 134 U/L, respectively. In these dogs a concurrent increase in AST values was registered, also ( Figure 7) .
The true reasons for such an increase in serum AP and ALT activities during phenobarbitone therapy are still unclear. Results of previous studies indicate that the explanation for such an increase may be the induction of enzymes which results in increased concentrations of izoenzymes L-AP and C-AP within the hepatocytes and their subsequent release in the general circulation (Solter and Hoffmann, 1995; Deng et al., 1996) . In support of this theory is a paper (Gaskill et al., 2004) which claims that a significant increase in serum AP during phenobarbitone therapy is the result of increased activities of all three isoenzymes (C-AP, L-AP and B-AP).
The results published in this paper relative to AST activity in the first group of treated dogs support the hypothesis which claims that phenobarbitone does not induce enzymatically AST (Tettenborn et al., 1973; Müller et al., 2000) . However, the second group of dogs during treatment with 16 mg/kg/day phenobarbitone a total of 5 dogs (33%) had increased AST activities which were above the starting physiological referent values ( Figure 5) .
Two of the dogs with the highest AST values (111 U/L and 78 U/L) developed clinical symptoms of liver disease. During liver disease AST increases paralell to the activity of ALT (Center, 1995) which is in accordance to our finding in dogs suffering from hepatotoxicity. Studies on the diagnostic value of different liver enzymes in dogs with diagnosed liver disease indicate that an increase in serum AST is a more sensitive diagnostic tool compared to serum ALT activity (Abdeldaker and Hauge, 1986).
In the first group of dogs the significant decrease in albumin and total protein concentrations was of a transient nature as it was recorded only in the third week of the trial at 16 mg/kg/day phenobarbitone. The measured concentrations of albumins and total proteins in the first group were within the reference values and were independent of the duration of the phenobarbitone treatment.
In the second group of dogs suffering from idiopathic epilepsy a decreasing trend in albumin ( Figure 6 ) and total protein concentrations ( ) who reported the lack of a significant influence of phenobarbitone dose on albumin and total protein concentrations. Serum albumin concentration is often used as a non specific marker for hepatic function (Center, 1995) . Serum albumin concentrations below physiological values in phenobarbitone treated dogs are probably the result of its direct influence on albumin synthesis and/or its degradation (Mülleri et al., 2000) . It is considered that albumin levels below physiological values are the result of induced hepatic dysfunction (Chauvet et al., 1995) . This can be the rationale for our results as in the second group in two dogs hepatotoxicity was diagnosed. This is supported by the findings of Dayrell-Hart et al. (1991) , as well. Transient falls in serum albumin concentrations during phenobarbitone therapy have no major clinical importance (Müller et al., 2000) .
The short-lived statistically significant increase in triglyceride and cholesterol concentrations was determined in the first group of dogs during two measurements. However, no correlation between triglyceride and cholesterol concentrations and phenobarbitone dose and therapy duration was established. A cholesterol concentration below reference values was measured in one dog suffering from idiopathic epilepsy.
A cholesterol concentration below reference values was measured in one dog suffering from idiopathic epilepsy. This patient was treated with 16 mg/kg/day phenobarbitone and displayed clinical symptoms of idiopathic epilepsy. As cholesterol is synthetized in the liver the measured low concentration can be the result of the hepatic disfunction caused by phenobarbitone (Chauvet et al., 1995) .
All measured serum total bilirubin concentrations in the first group were within the reference values and were not significantly different from the values Total protein g/L measured before treatment. There was no link between the concentration of total bilirubin and time and dose of applied phenobarbitone. However, in the second experimental group a statistically significant increase in plasma total bilirubin was measured in dogs treated with 16 mg/kg/day phenobarbitone ( Figure 8 ). The concentration of total bilirubin did not change depending on dose or duration of the treatment (Chauvet et al., 1995; Foster et al., 2000) .
Measurements above referent values for total bilirubin can be the result of phenobarbitone hepatotoxicity (Dayrell -Hart et al., 1991) or as an artifact due to lipemic serum samples (Willard and Twedt, 1994; Burkhard and Meyer, 1995) . This was registered in two dogs treated with 16 mg/kg/day phenobarbitone and suffering from hepatotoxicity had readings for plasma bilirubin above the reference values.
Glucose concentration did not significantly change depending on phenobarbitone dose or duration of treatment. All glucose measurements were well within the physiological range in both experimental groups.
No relationship between phenobarbitone treatment and blood urea and creatinine concentration was established. The transient statistically significant difference in urea and creatinine concentration during one sampling was of no clinical significance.
